睿知中国医院研究地图
候选清单

即将招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07684456,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients who have received non-investigational anti-tumor therapies within 4 weeks prior to study drug administration.

    排除标准第 1 条

    Patients who have received any major surgery(except for diagnostic procedures such as biopsy),or have sustained major trauma within 4 weeks to randomization;or is expected to undergo major surgery during the treatment.

    排除标准第 12 条

    Patients who have received radiotherapy within 2 weeks to randomization.

    排除标准第 13 条

  3. Male or female subjects with ECOG performance status scored 0-1.

    入选标准第 3 条

  4. At least one measurable lesion present according to RECIST 1.1 criteria.

    入选标准第 8 条

  5. Patients with other malignant tumor within 5 years to randomization excluding curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma, and papillary thyroid carcinoma.

    排除标准第 15 条

  6. Fertile males and females of childbearing potential must agree to use effective contraception (so do their partners, using hormonal or barrier contraception, or abstinence) during the study and within at least 6 months after the last dose. The blood or urine pregnancy test for female patients of childbearing potential prior to enrollment must be negative.

    入选标准第 12 条

    Pregnant or lactating patients.

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07684456,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients who have fully understood the objectives, content, process of the study and possible adverse events, voluntarily serves as a subject and signs the informed consent form.
  2. Subjects aged ≥18 and ≤75.
  3. Male or female subjects with ECOG performance status scored 0-1.
  4. Patients who were diagnosed with HER-2 negative advanced breast cancer by histopathology.
  5. Patients with locally advanced,recurrent,or metastatic breast cancer.
  6. Patients who had received chemotherapy regimens, including at least one taxanes or anthracyclines.
  7. Patients with hormone receptor positive should have disease progression after endocrine therapy.
  8. At least one measurable lesion present according to RECIST 1.1 criteria.
  9. Expected survival time ≥ 12 weeks
  10. Baseline routine blood tests is normal.
  11. Liver and kidney function test results are normal.
  12. Fertile males and females of childbearing potential must agree to use effective contraception (so do their partners, using hormonal or barrier contraception, or abstinence) during the study and within at least 6 months after the last dose. The blood or urine pregnancy test for female patients of childbearing potential prior to enrollment must be negative.

排除标准:Exclusion Criteria:

  1. Patients who have received non-investigational anti-tumor therapies within 4 weeks prior to study drug administration.
  2. Patients who have used Capecitabine or Utidelone within 6 months prior to randomization.
  3. Patients with breast cancer with CNS metastases leptomeningeal metastases.
  4. Patients with uncontrollable bone metastases,existing or recent risk of fracture, recent need for surgery or local radiotherapy, or other critical conditions.
  5. Patients with uncontrollable pleural effusion,pericardial effusion or ascites requiring repeated drainage(once a month or more)
  6. Patients with serious cardiovascular disease.
  7. Patients with mental illnesses which are hard to control, patients who lack legal capacity or have limited legal capacity.
  8. Patients with gastrointestinal disorders affecting oral administration.
  9. Patients with active infections and need systemic therapy currently.
  10. Patients with peripheral neuropathy grade≥2 during randomization.
  11. Patients with toxicity grade ≥2 which caused by prior anti-tumor therapy.(NCI-CTCAE 5.0,except for what is considered no safety risk such as alopecia by investigator.)
  12. Patients who have received any major surgery(except for diagnostic procedures such as biopsy),or have sustained major trauma within 4 weeks to randomization;or is expected to undergo major surgery during the treatment.
  13. Patients who have received radiotherapy within 2 weeks to randomization.
  14. Patients who have received interventional therapy in another clinical trail or have received other investigational treatments.
  15. Patients with other malignant tumor within 5 years to randomization excluding curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma, and papillary thyroid carcinoma.
  16. Patients with allergy of caster oil:patients with previous fluorouracil medication history with severe allergy or known dihydropyrimidine dehydrogenase (DPD) deficiency;
  17. Pregnant or lactating patients.
  18. Patients who, in the opinion of the investigator, are not suitable to participate in this study.

引自 ClinicalTrials.gov, NCT07684456, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07684456,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07684456